How it works:
Selectively binds to CD20 antigen on B-lymphocytes
Induces their destruction, halting disease progression
Reduces inflammation in autoimmune conditions
Recommended for:
Patients with non-Hodgkin’s B-cell lymphoma
Chronic lymphocytic leukaemia cases
Severe rheumatoid arthritis
CD20-positive disorders under medical supervision
Non-Hodgkin’s lymphoma (including follicular type)
Chronic lymphocytic leukaemia
Rheumatoid arthritis (in combination with methotrexate)
Granulomatosis with polyangiitis, microscopic polyangiitis
Administered intravenously via drip infusion under hospital conditions after dilution. Dosage and treatment duration are defined individually by a specialist.
Contraindications
Hypersensitivity to Rituximab or murine proteins
Severe active infections
Advanced heart failure
Paediatric use (unless otherwise directed)
Adverse Effects
Fever, chills, fatigue
Skin reactions (rash, itching)
Bronchospasm, cough
Hypotension, arrhythmia
Increased risk of infections